Anifrolumab (Saphnelo)
Canadian Journal of Health Technologies · 20.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 20.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses anifrolumab (SAPHNELO), 120 mg in 0.8mL, solution for injection, sub-cutaneous. Indication: Is indicated in addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus (SLE).
Zitieren
APA
CDA-AMC (2026). Anifrolumab (Saphnelo). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1545
Vancouver
CDA-AMC. Anifrolumab (Saphnelo). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1545
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Anifrolumab (Saphnelo)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1545}
}
EUVIMED